secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0000950170-22-025912
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears Pyxis Oncology INDs for PYX-201 ADC and PYX-106 immunotherapy
------------------------------------------------------------------------

- FDA cleared IND for PYX-201, an ADC targeting tumor microenvironment for breast, head/neck, lung, thyroid cancers.
- FDA cleared IND for PYX-106, an immunotherapy targeting Siglec-15 for bladder, cholangiocarcinoma, colorectal, kidney cancers.
- Phase 1 trials planned to start in early 2023; cash runway extended into first half 2025.
- Pyxis Oncology transitions to clinical-stage company with veteran leadership team.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017022025912/0000950170-22-025912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017022025912/pyxs-20221201.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-025912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer